GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jiangsu Jibeier Pharmaceutical Co 688566.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

25.55

-0.78%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Jiangsu Jibeier Pharmaceutical Co

Its shares trade on Shanghai under the ticker 688566.SS. It has been listed since 18 May 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥964.9m and net income of CN¥258.7m. At that date it held total assets of CN¥2.72bn and shareholders' equity of CN¥2.43bn.

Jiangsu Jibeier Pharmaceutical Co. Ltd. engages in the research, development, preparation and manufacturing of pharmaceutical products. The company is headquartered in Zhenjiang, Jiangsu. The company went IPO on 2020-05-18. The firm's products are comprised of tablets, capsules and eye drops. The tablet products include Leucogen tablets, Nitrendipine and Atenolol tablets, Aceclofenac Enteric-coated tablets and Asarone tablets. The firm's products are used to improve white blood cells, treat high blood pressure, eye infections and other diseases.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
18 May 2020
Employees
1,016

Leadership

Pay as last reported

  • Mr. Zhongyi GengChairman of the Board, General Manager, since 2014CN¥1.4m
  • Mr. Xinjun YuVice Chairman of the Board, Deputy General Manager, since 2014CN¥768,000
  • Mr. Suofu ZhaoChief Financial OfficerCN¥692,100
  • Ms. Ying WuDeputy General Manager,Chief EngineerCN¥681,600
  • Mr. Chun ZhangFacilities Director, Director, since 2020CN¥692,100
  • Mr. Jianzhong DiSecretary of the BoardCN¥692,100
  • Mr. Tao HuDirector
  • Mr. Liuping ChenIndependent Director
  • Mr. Ming FanIndependent Director
  • Mr. Tongjun LiuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company employs 1016 full-time employees
  • Headquartered in Zhenjiang, Jiangsu
  • Products include tablets, capsules, and eye drops

Weaknesses

  • No specific product sales figures provided
  • No mention of R&D investment details
  • No information on market share or competitive position

Opportunities

  • Potential growth in pharmaceutical sector in China
  • IPO in 2020 may provide capital for expansion
  • Diverse product portfolio including treatments for high blood pressure and eye infections

Threats

  • Unspecified competition in pharmaceutical industry
  • Dependence on unmentioned regulatory approvals
  • No data on potential market saturation

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.